Summary & Overview
HCPCS Q3027: Interferon Beta-1a Injection, 1 mcg IM
HCPCS Level II code Q3027 denotes a 1 mcg intramuscular injection of interferon beta-1a, a biologic therapy used in clinical settings that require intramuscular administration. Nationally, accurate coding of this product matters for clinical documentation, benefit determination, and consistent claims processing for injectable disease-modifying therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns and administrative benchmarks where available, highlights clinical context for intramuscular interferon beta-1a, and outlines typical places of service for administration.
Readers will find concise benchmarks for reimbursement and utilization practices (where available), a review of coding and billing considerations tied to HCPCS Level II code Q3027, and the clinical service context for intramuscular administration. The report also identifies areas where standardization of claims submission and site-of-service designation can affect payment and administrative workflows. Data not provided in the input is noted as unavailable and not inferred.
Billing Code Overview
HCPCS Level II code Q3027 represents injection, interferon beta-1a, 1 mcg for intramuscular use. This code describes a single-dose injectable formulation of interferon beta-1a administered via intramuscular injection. The service type is injectable biologic therapy for conditions indicated for interferon beta-1a. The typical site of service is outpatient clinic, physician office, or other ambulatory care settings where intramuscular injections are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with relapsing-remitting multiple sclerosis presents to an outpatient clinic for scheduled intramuscular disease-modifying therapy. The medication administered is interferon beta-1a, supplied and billed as Q3027 (Injection, interferon beta-1a, 1 mcg for intramuscular use). The usual clinical workflow includes verification of the patient’s identity and insurance, review of recent laboratory results (including liver function tests and CBC), assessment for intercurrent infection or contraindications, informed consent and counseling on potential side effects (flu-like symptoms, injection-site reactions), preparation of the dose by nursing staff, and administration via a single intramuscular injection into the deltoid or anterolateral thigh. Post-injection observation for immediate adverse reactions typically occurs for 15–30 minutes. Documentation includes medication name and Q3027 billing code, lot number and expiration, injection site, route (intramuscular), patient vital signs before and after administration, and any adverse events. Billing may occur under the patient’s medical benefit; common payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; default submission |